Treatment of secretory diarrhea in AIDS with the somatostatin analogue SMS 201-995

Füeßl, Hermann S.; Zoller, WG; Kochen, Michael M.; Bogner, Johannes R.; Heinrich, Bernd; Matuschke, A.; Goebel, Frank-Detlef

doi:10.1007/bf01725142

Cited by 13 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, octreotide may prolong intestinal transit time (31). Octreotide has been used to treat the secretory diarrhea associated with Zollinger-Ellison syndrome, carcinoid syndrome, acquired immunodeficiency syndrome (AIDS), multiple endocrine neoplasia-2A, and graft-versus-host disease (GVHD) (11,(32)(33)(34)(35). Other case reports have demonstrated the possible efficacy of octreotide for treatment of diarrhea occurring as a result of hemicolectomy, scleroderma, celiac plexus block, and villous adenoma of the rectum (36)(37)(38)(39).…”

Section: Diarrheamentioning

confidence: 99%

“…In animal models, HIV protein peptide fragments provoke fluid and electrolyte secretion by rat colonic mucosa, and this effect is reversible with octreotide (54). The administration of octreotide was associated with a decrease in stool volume and a decrease in the number of bowel movements in two patients with AIDS whose secretory diarrhea was caused by infection with Cryptosporidium (35). Simon et al (51) performed a multi‐center, two‐phase trial in patients with AIDS‐associated diarrhea who failed treatment with standard anti‐diarrhea therapy.…”

Section: Specific Uses Of Octreotidementioning

confidence: 99%

See 1 more Smart Citation

Octreotide in Pediatric Patients

Heikenen,

Pohl,

Werlin

et al. 2002

J. pediatr. gastroenterol. nutr.

View full text Add to dashboard Cite

Section: Diarrheamentioning

confidence: 99%

Section: Specific Uses Of Octreotidementioning

confidence: 99%

Octreotide in Pediatric Patients

Heikenen,

Pohl,

Werlin

et al. 2002

J. pediatr. gastroenterol. nutr.

View full text Add to dashboard Cite

Randomized trial of loperamide versus dose escalation of octreotide acetate for chemotherapy‐induced diarrhea in bone marrow transplant and leukemia patients

et al. 1995

View full text Add to dashboard Cite

This study compares maximal daily doses of loperamide to escalating doses of continuous intravenous (CI) octreotide acetate in bone marrow transplant (BMT) and leukemia patients. Following chemotherapy, BMT and leukemia patients who developed > or = 600 ml of stool volume in a 24-hr period were randomized to receive loperamide 4 mg po q6h or octreotide 150 micrograms mixed in hyperalimentation solution or normal saline and administered CI. Patients were assessed at 48 hr intervals for decrease in stool volume from baseline. Complete response (CR) was defined as > or = 50% from baseline stool volume (BSV). Patients receiving octreotide who did not achieve a CR at 48 hr were dose escalated by doubling the dose to a maximum of 2,400 micrograms with evaluations at 48 hr intervals. Patients receiving loperamide who did not achieve a CR at 48 hr had treatment discontinued. A total of 36 patients were enrolled in the study. Of these, all were evaluable for intention to treat, and 31 were evaluable for initial response. Based on intent to treat at the initial 48 hr, patients receiving loperamide had a higher complete response rate (86% vs. 45%, P = 0.033) than did those who received octreotide. By treatment analysis (patients who actually received the drug), patients receiving loperamide had a higher complete response rate (92% vs. 56%, P = 0.0448) than did those who received octreotide at the 150 micrograms dosage level. Additional octreotide patients eventually achieved a CR at a higher dosage level (78%). Loperamide at maximal doses of 4 mg po q6h is more effective than octreotide 150 micrograms CI in treating diarrhea following chemotherapy in BMT and leukemia patients. Higher doses of octreotide may be required in a significant number of patients not responding to lower doses.

show abstract

Treatment of severe postvagotomy/postgastrectomy symptoms with the somatostatin analogue octreotide

Mackie

Jenkins

Hartley

1991

British Journal of Surgery

View full text Add to dashboard Cite

Fourteen patients with severe and persistent postvagotomy/postgastrectomy symptoms were entered into a trial of treatment with the somatostatin analogue octreotide, 50 micrograms twice daily 30 min before meals being self-administered by subcutaneous injection. Six of the seven patients completing the 3-month trial showed sustained overall improvement of symptoms. The remaining patients were unhelped by treatment or developed unwanted effects. Six of eight patients with dumping syndrome showed sustained improvement of dumping symptoms during treatment. Bile vomiting was relieved in three of four patients with this complaint. Diarrhoea accompanying dumping showed a variable response to treatment, with improvement in three patients and no change or worsening of this symptom in five. Two patients with severe postvagotomy diarrhoea alone showed no improvement. Four patients with unwanted effects and three patients who found no benefit stopped the trial medication early. Four further patients reported mild or transient side-effects. For patients with severe postvagotomy/postgastrectomy symptoms, a trial of octreotide seems justified when significant dumping symptoms are present and other treatment options have been exhausted.

show abstract

Treatment of secretory diarrhea in AIDS with the somatostatin analogue SMS 201-995

Cited by 13 publications

References 16 publications

Octreotide in Pediatric Patients

Octreotide in Pediatric Patients

Randomized trial of loperamide versus dose escalation of octreotide acetate for chemotherapy‐induced diarrhea in bone marrow transplant and leukemia patients

Treatment of severe postvagotomy/postgastrectomy symptoms with the somatostatin analogue octreotide

Contact Info

Product

Resources

About